SBI-477 is primarily used in biochemical and pharmaceutical research for its ability to modulate specific cellular pathways involved in metabolism and cell proliferation. It has been studied for its potential to inhibit certain protein-protein interactions that play a role in cancer progression, particularly in leukemia. By targeting transcriptional co-regulators, SBI-477 can disrupt the activity of oncogenic transcription factors, making it a valuable tool compound in the development of novel anti-cancer therapies. Its application extends to research on metabolic diseases due to its effects on insulin signaling and glucose homeostasis. SBI-477 is mainly utilized in preclinical studies to understand disease mechanisms and to validate therapeutic targets.